TARA

insider transactions

Protara Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 17, 26

Richard S Levy

Director

$0

766 sh

Own New
Grant·A
Jun 17, 26

Richard S Levy

Director

$0

454 sh

Own +2%
Grant·A
Jun 15, 26

Michael Edward Solomon

Director

$0

31.0K sh

Own New
Grant·A
Jun 15, 26

Cynthia Smith

Director

$0

31.0K sh

Own New
Grant·A
Jun 15, 26

Gregory Sargen

Director

$0

31.0K sh

Own New
Grant·A
Jun 15, 26

Richard S Levy

Director

$0

31.0K sh

Own New
Grant·A
Jun 15, 26

Jane Huang

Director

$0

31.0K sh

Own New
Grant·A
Jun 15, 26

Roger Garceau

Director

$0

31.0K sh

Own New
Grant·A
Jun 15, 26

Barry P Flannelly

Director

$0

31.0K sh

Own New
Grant·A
Jun 15, 26

Luke M Beshar

Director

$0

31.0K sh

Own New
Grant·A
Jun 9, 26

William Conkling

Director

$37.5K

673 sh · $55.75

Own New
Other·F
Jun 2, 26

William Conkling

Chief Commercial Officer

$26.1K

6.0K sh · $4.34

Own -8%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 17, 2026	Richard S Levy	Director	Grant A	766	New	—	$0
Jun 17, 2026	Richard S Levy	Director	Grant A	454	+2%	—	$0
Jun 15, 2026	Michael Edward Solomon	Director	Grant A	31.0K	New	—	$0
Jun 15, 2026	Cynthia Smith	Director	Grant A	31.0K	New	—	$0
Jun 15, 2026	Gregory Sargen	Director	Grant A	31.0K	New	—	$0
Jun 15, 2026	Richard S Levy	Director	Grant A	31.0K	New	—	$0
Jun 15, 2026	Jane Huang	Director	Grant A	31.0K	New	—	$0
Jun 15, 2026	Roger Garceau	Director	Grant A	31.0K	New	—	$0
Jun 15, 2026	Barry P Flannelly	Director	Grant A	31.0K	New	—	$0
Jun 15, 2026	Luke M Beshar	Director	Grant A	31.0K	New	—	$0
Jun 9, 2026	William Conkling	Director	Grant A	673	New	$55.75	$37.5K
Jun 2, 2026	William Conkling	Chief Commercial Officer	Other F	6.0K	-8%	$4.34	$26.1K

About TARA insider trading

This page tracks insider transactions for Protara Therapeutics, Inc. (TARA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.